The protein acetyltransferase ARD1: A novel cancer drug target?

Current Cancer Drug Targets

Volumn 8, Issue 7, 2008, Pages 545-553

  Arnesen, Thomas ^a,b   Thompson, Paul R ^c   Varhaug, Jan Erik ^a,b   Lillehaug, Johan R ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Apoptosis; Cell cycle arrest; Co translational; hARD1; HIF 1 ; N terminal; NATH; Protein acetylation

Indexed keywords

ACETIC ACID DERIVATIVE; ACETYL COENZYME A; ACYLTRANSFERASE; BETA CATENIN; HISTONE ACETYLTRANSFERASE; PROTEIN ARD1; PROTEIN NATH; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR TCF4; UNCLASSIFIED DRUG;

ACETYLATION; AMINO TERMINAL SEQUENCE; APOPTOSIS; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; COMPLEX FORMATION; DOWN REGULATION; DRUG TARGETING; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; NONHUMAN; PROTEIN PROTEIN INTERACTION; REVIEW; THYROID PAPILLARY CARCINOMA; TUMOR DIFFERENTIATION; UPREGULATION;

ACETYLTRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; GROWTH INHIBITORS; HUMANS; NEOPLASMS;

EID: 55449133307     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800908786241113     Document Type: Review

References (75)

1. Byrd, J. C.; Marcucci, G.; Parthun, M. R.; Xiao, J. J.; Klisovic, R. B.; Moran, M.; Lin, T. S.; Liu, S.; Sklenar, A. R.; Davis, M. E.; Lucas, D. M.; Fischer, B.; Shank, R.; Tejaswi, S. L.; Binkley, P.; Wright, J.; Chan, K. K.; Grever, M. R. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005, 105, 959-967.
2. Kelly, W. K.; Richon, V. M.; O'Connor, O.; Curley, T.; MacGregor-Curtelli, B.; Tong, W.; Klang, M.; Schwartz, L.; Richardson, S.; Rosa, E.; Drobnjak, M.; Cordon-Cordo, C.; Chiao, J. H.; Rifkind, R.; Marks, P. A.; Scher, H. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 2003, 9, 3578-3588.
3. Kelly, W. K.; Marks, P. A. Drug insight: Histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat. Clin. Pract. Oncol. 2005, 2, 150-157.
4. Patnaik, A.; Rowinsky, E. K.; Villalona, M. A.; Hammond, L. A.; Britten, C. D.; Siu, L. L.; Goetz, A.; Felton, S. A.; Burton, S.; Valone, F. H.; Eckhardt, S. G. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin. Cancer Res. 2002, 8, 2142-2148.
5. Piekarz, R. L.; Robey, R.; Sandor, V.; Bakke, S.; Wilson, W. H.; Dahmoush, L.; Kingma, D. M.; Turner, M. L.; Altemus, R.; Bates, S. E. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001, 98, 2865-2868.
6. Piekarz, R. L.; Robey, R. W.; Zhan, Z.; Kayastha, G.; Sayah, A.; Abdeldaim, A. H.; Torrico, S.; Bates, S. E. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 2004, 103, 4636-4643.
7. Pilatrino, C.; Cilloni, D.; Messa, E.; Morotti, A.; Giugliano, E.; Pautasso, M.; Familiari, U.; Cappia, S.; Pelicci, P. G.; Lo, C. F.; Saglio, G.; Guerrasio, A. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer 2005, 104, 101-109.
8. Raffoux, E.; Chaibi, P.; Dombret, H.; Degos, L. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica 2005, 90, 986-988.
9. Sandor, V.; Bakke, S.; Robey, R. W.; Kang, M. H.; Blagosklonny, M. V.; Bender, J.; Brooks, R.; Piekarz, R. L.; Tucker, E.; Figg, W. D.; Chan, K. K.; Goldspiel, B.; Fojo, A. T.; Balcerzak, S. P.; Bates S. E. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 2002, 8, 718-728.
10. Polevoda, B.; Sherman, F. N-terminal acetyltransferases and sequence requirements for N-terminal acetylation of eukaryotic proteins. J. Mol. Biol. 2003, 325, 595-622.
11. Arnold, R. J.; Polevoda, B.; Reilly, J. P.; Sherman, F. The action of N-terminal acetyltransferases on yeast ribosomal proteins. J. Biol. Chem. 1999, 274, 37035-37040.
12. Polevoda, B.; Norbeck, J.; Takakura, H.; Blomberg, A.; Sherman, F. Identification and specificities of N-terminal acetyltransferases from Saccharomyces cerevisiae. EMBO J. 1999, 18, 6155-6168.
13. Mullen, J. R.; Kayne, P. S.; Moerschell, R. P.; Tsunasawa, S.; Gribskov, M.; Colavito-Shepanski, M.; Grunstein, M.; Sherman, F.; Sternglanz, R. Identification and characterization of genes and mutants for an N-terminal acetyltransferase from yeast. EMBO J. 1989, 8, 2067-2075.
14. Park, E. C.; Szostak, J. W. ARD1 and NAT1 proteins form a complex that has N-terminal acetyltransferase activity. EMBO J. 1992, 11, 2087-2093.
15. Gautschi, M.; Just, S.; Mun, A.; Ross, S.; Rucknagel, P.; Dubaquie, Y.; Ehrenhofer-Murray, A.; Rospert, S. The yeast N(alpha)-acetyltransferase NatA is quantitatively anchored to the ribosome and interacts with nascent polypeptides. Mol. Cell Biol. 2003, 23, 7403-7414.
16. Lee, F. J.; Lin, L. W.; Smith, J. A. N alpha acetylation is required for normal growth and mating of Saccharomyces cerevisiae. J. Bacteriol. 1989, 171, 5795-5802.
17. Whiteway, M.; Szostak, J. W. The ARD1 gene of yeast functions in the switch between the mitotic cell cycle and alternative developmental pathways. Cell 1985, 43, 483-492.
18. Whiteway, M.; Freedman, R.; Van Arsdell, S.; Szostak, J. W.; Thorner, J. The yeast ARD1 gene product is required for repression of cryptic mating-type information at the HML locus. Mol. Cell Biol. 1987, 7, 3713-3722.
19. Aparicio, O. M.; Billington, B. L.; Gottschling, D. E. Modifiers of position effect are shared between telomeric and silent mating-type loci in S. cerevisiae. Cell 1991, 66, 1279-1287.
20. Geissenhoner, A.; Weise, C.; Ehrenhofer-Murray, A. E. Dependence of ORC silencing function on NatA-mediated Nalpha acetylation in Saccharomyces cerevisiae. Mol. Cell Biol. 2004, 24, 10300-10312.
21. Wang, X.; Connelly, J. J.; Wang, C. L.; Sternglanz, R. Importance of the Sir3 N terminus and its acetylation for yeast transcriptional silencing. Genetics 2004, 168, 547-551.
22. Lu, L.; Berkey, K. A.; Casero, R. A., Jr. RGFGIGS is an amino acid sequence required for acetyl coenzyme A binding and activity of human spermidine/spermine N1acetyltransferase. J. Biol. Chem. 1996, 271, 18920-18924.
23. Neuwald, A. F.; Landsman, D. GCN5-related histone N-acetyltransferases belong to a diverse superfamily that includes the yeast SPT10 protein. Trends Biochem. Sci. 1997, 22, 154-155.
24. Asaumi, M.; Iijima, K.; Sumioka, A.; Iijima-Ando, K.; Kirino, Y.; Nakaya, T.; Suzuki, T. Interaction of N-terminal acetyltransferase with the cytoplasmic domain of beta-amyloid precursor protein and its effect on A beta secretion. J. Biochem. (Tokyo) 2005, 137, 147-155.
25. Linding, R.; Russell, R. B.; Neduva, V.; Gibson, T. J. GlobPlot: Exploring protein sequences for globularity and disorder. Nucleic Acids Res. 2003, 31, 3701-3708.
26. Cuff, J. A.; Barton, G. J. Application of multiple sequence alignment profiles to improve protein secondary structure prediction. Proteins 2000, 40, 502-511.
27. Sanchez-Puig, N.; Fersht, A. R. Characterization of the native and fibrillar conformation of the human Nalpha-acetyltransferase ARD1. Protein Sci. 2006, 15, 1968-1976.
28. Arnesen, T.; Anderson, D.; Baldersheim, C.; Lanotte, M.; Varhaug, J. E.; Lillehaug, J. R. Identification and characterization of the human ARD1-NATH protein acetyltransferase complex. Biochem. J. 2005, 386, 433-443.
29. Chou, K. C. Structural bioinformatics and its impact to biomedical science. Curr. Med. Chem. 2004, 11, 2105-2134.
30. Thornberry, N. A.; Rano, T. A.; Peterson, E. P.; Rasper, D. M.; Timkey, T.; Garcia-Calvo, M.; Houtzager, V. M.; Nordstrom, P. A.; Roy, S.; Vaillancourt, J. P.; Chapman, K. T.; Nicholson, D. W. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J. Biol. Chem. 1997, 272, 17907-17911.
31. Arnesen, T.; Betts, M. J.; Pendino, F.; Liberles, D. A.; Anderson, D.; Caro, J.; Kong, X.; Varhaug, J. E.; Lillehaug, J. R. Characterization of hARD2, a processed hARD1 gene duplicate, encoding a human protein N-alpha- acetyltransferase. BMC. Biochem. 2006, 7, 13.
32. Sugiura, N.; Adams, S. M.; Corriveau, R. A. An evolutionarily conserved N-terminal acetyltransferase complex associated with neuronal development. J. Biol. Chem. 2003, 278, 40113-40120.
33. Arnesen, T.; Anderson, D.; Torsvik, J.; Halseth, H. B.; Varhaug, J. E.; Lillehaug, J. R. Cloning and characterization of hNAT5/hSAN: an evolutionarily conserved component of the NatA protein N-alpha-acetyltransferase complex. Gene 2006, 371, 291-295.
34. Williams, B. C.; Garrett-Engele, C. M.; Li, Z.; Williams, E. V.; Rosenman, E. D.; Goldberg, M. L. Two putative acetyltransferases, san and deco, are required for establishing sister chromatid cohesion in Drosophila. Curr. Biol. 2003, 13, 2025-2036.
35. Brennan, C. A.; Delaney, J. R.; Schneider, D. S.; Anderson, K. V. Psidin is required in Drosophila blood cells for both phagocytic degradation and immune activation of the fat body. Curr. Biol. 2007, 17, 67-72.
36. Gendron, R. L.; Adams, L. C.; Paradis, H. Tubedown-1, a novel acetyltransferase associated with blood vessel development. Dev. Dyn. 2000, 218, 300-315.
37. Ingram, A. K.; Cross, G. A.; Horn, D. Genetic manipulation indicates that ARD1 is an essential N(infinity)-acetyltransferase in Trypanosoma brucei. Mol. Biochem. Parasitol. 2000, 111, 309-317.
38. Pesaresi, P.; Gardner, N. A.; Masiero, S.; Dietzmann, A.; Eichacker, L.; Wickner, R.; Salamini, F.; Leister, D. Cytoplasmic N-terminal protein acetylation is required for efficient photosynthesis in Arabidopsis. Plant Cell 2003, 15, 1817-1832.
39. Wenzlau, J. M.; Garl, P. J.; Simpson, P.; Stenmark, K. R.; West, J.; Artinger, K. B.; Nemenoff, R. A.; Weiser-Evans, M. C. Embryonic growth-associated protein is one subunit of a novel N-terminal acetyltransferase complex essential for embryonic vascular development. Circ. Res. 2006, 98, 846-855.
40. Sonnichsen, B.; Koski, L. B.; Walsh, A.; Marschall, P.; Neumann, B.; Brehm, M.; Alleaume, A. M.; Artelt, J.; Bettencourt, P.; Cassin, E.; Hewitson, M.; Holz, C.; Khan, M.; Lazik, S.; Martin, C.; Nitzsche, B.; Ruer, M.; Stamford, J.; Winzi, M.; Heinkel, R.; Roder, M.; Finell, J.; Hantsch, H.; Jones, S. J.; Jones, M.; Piano, F.; Gunsalus, K. C.; Oegema, K.; Gonczy, P.; Coulson, A.; Hyman, A. A.; Echeverri, C. J. Full-genome RNAi profiling of early embryogenesis in Caenorhabditis elegans. Nature 2005, 434, 462-469.
41. Fisher, T. S.; Etages, S. D.; Hayes, L.; Crimin, K.; Li, B. Analysis of ARD1 function in hypoxia response using retroviral RNA interference. J. Biol. Chem. 2005, 280, 17749-17757.
42. Arnesen, T.; Gromyko, D.; Pendino, F.; Ryningen, A.; Varhaug, J. E.; Lillehaug, J. R. Induction of apoptosis in human cells by RNAi-mediated knockdown of hARD1 and NATH, components of the protein N-alpha-acetyltransferase complex. Oncogene 2006, 25, 4350-4360.
43. Lim, J. H.; Park, J. W.; Chun, Y. S. Human arrest defective 1 acetylates and activates beta-catenin, promoting lung cancer cell proliferation. Cancer Res. 2006, 66, 10677-10682.
44. Hou, F.; Chu, C. W.; Kong, X.; Yokomori, K.; Zou, H. The acetyltransferase activity of San stabilizes the mitotic cohesin at the centromeres in a shugoshin-independent manner. J. Cell Biol. 2007, 177, 587-597.
45. Yi, C. H.; Sogah, D. K.; Boyce, M.; Degterev, A.; Christofferson, D. E.; Yuan, J. A genome-wide RNAi screen reveals multiple regulators of caspase activation. J. Cell Biol. 2007, 179, 619-626.
46. Fluge, O.; Bruland, O.; Akslen, L. A.; Varhaug, J. E.; Lillehaug, J. R. NATH, a novel gene overexpressed in papillary thyroid carcinomas. Oncogene 2002, 21, 5056-5068.
47. Arnesen, T.; Gromyko, D.; Horvli, O.; Fluge, O.; Lillehaug, J.; Varhaug, J. E. Expression of N-acetyl transferase human and human Arrest defective 1 proteins in thyroid neoplasms. Thyroid 2005, 15, 1131-1136.
48. Line, A.; Stengrevics, A.; Slucka, Z.; Li, G.; Jankevics, E.; Rees, R. C. Serological identification and expression analysis of gastric cancer-associated genes. Br. J. Cancer 2002, 86, 1824-1830.
49. Midorikawa, Y.; Tsutsumi, S.; Taniguchi, H.; Ishii, M.; Kobune, Y.; Kodama, T.; Makuuchi, M.; Aburatani, H. Identification of genes associated with dedifferentiation of hepatocellular carcinoma with expression profiling analysis. Jpn. J. Cancer Res. 2002, 93, 636-643.
50. Ren, T.; Jiang, B.; Jin, G.; Li, J.; Dong, B.; Zhang, J.; Meng, L.; Wu, J.; Shou, C. Generation of novel monoclonal antibodies and their application for detecting ARD1 expression in colorectal cancer. Cancer Lett. 2008, 264, 83-92.
51. Paradis, H.; Liu, C. Y.; Saika, S.; Azhar, M.; Doetschman, T.; Good, W. V.; Nayak, R.; Laver, N.; Kao, C. W.; Kao, W. W.; Gendron, R. L. Tubedown-1 in remodeling of the developing vitreal vasculature in vivo and regulation of capillary outgrowth in vitro. Dev. Biol. 2002, 249, 140-155.
52. Sugiura, N.; Patel, R. G.; Corriveau, R. A. N-methyl-D-aspartate receptors regulate a group of transiently expressed genes in the developing brain. J. Biol. Chem. 2001, 276, 14257-14263.
53. Martin, D. T.; Gendron, R. L.; Jarzembowski, J. A.; Perry, A.; Collins, M. H.; Pushpanathan, C.; Miskiewicz, E.; Castle, V. P.; Paradis, H. Tubedown expression correlates with the differentiation status and aggressiveness of neuroblastic tumors. Clin. Cancer Res. 2007, 13, 1480-1487.
54. Metzen, E.; Ratcliffe, P. J. HIF hydroxylation and cellular oxygen sensing. Biol. Chem. 2004, 385, 223-230.
55. Jeong, J. W.; Bae, M. K.; Ahn, M. Y.; Kim, S. H.; Sohn, T. K.; Bae, M. H.; Yoo, M. A.; Song, E. J.; Lee, K. J.; Kim, K. W. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002, 111, 709-720.
56. Arnesen, T.; Kong, X.; Evjenth, R.; Gromyko, D.; Varhaug, J. E.; Lin, Z.; Sang, N.; Caro, J.; Lillehaug, J. R. Interaction between HIF-1 alpha (ODD) and hARD1 does not induce acetylation and destabilization of HIF-1 alpha. FEBS Lett. 2005, 579, 6428-6432.
57. Bilton, R.; Mazure, N.; Trottier, E.; Hattab, M.; Dery, M. A.; Richard, D. E.; Pouyssegur, J.; Brahimi-Horn, M. C. Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1alpha and is not induced by hypoxia or HIF. J. Biol. Chem. 2005, 280, 31132-31140.
58. Murray-Rust, T. A.; Oldham, N. J.; Hewitson, K. S.; Schofield, C. J. Purified recombinant hARD1 does not catalyse acetylation of Lys532 of HIF-1alpha fragments in vitro. FEBS Lett. 2006, 580, 1911-1918.
59. Kim, S. H.; Park, J. A.; Kim, J. H.; Lee, J. W.; Seo, J. H.; Jung, B. K.; Chun, K. H.; Jeong, J. W.; Bae, M. K.; Kim, K. W. Characterization of ARD1 variants in mammalian cells. Biochem. Biophys. Res. Commun. 2006, 340, 422-427.
60. Chang, C. C.; Lin, M. T.; Lin, B. R.; Jeng, Y. M.; Chen, S. T.; Chu, C. Y.; Chen, R. J.; Chang, K. J.; Yang, P. C.; Kuo, M. L. Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis. J. Natl. Cancer Inst. 2006, 98, 984-995.
61. Fath, D. M.; Kong, X.; Liang, D.; Lin, Z.; Chou, A.; Jiang, Y.; Fang, J.; Caro, J.; Sang, N. Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha. J. Biol. Chem. 2006, 281, 13612-13619.
62. Kong, X.; Lin, Z.; Liang, D.; Fath, D.; Sang, N.; Caro, J. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol. Cell Biol. 2006, 26, 2019-2028.
63. Lim, J. H.; Chun, Y. S.; Park, J. W. Hypoxia-inducible factor-1alpha obstructs a Wnt signaling pathway by inhibiting the hARD1-mediated activation of beta-catenin. Cancer Res. 2008, 68, 5177-5184.
64. Lau, O. D.; Kundu, T. K.; Soccio, R. E.; Ait-Si-Ali, S.; Khalil, E. M.; Vassilev, A.; Wolffe, A. P.; Nakatani, Y.; Roeder, R. G.; Cole, P. A. HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol. Cell 2000, 5, 589-595.
65. Thompson, P. R.; Kurooka, H.; Nakatani, Y.; Cole, P. A. Transcriptional coactivator protein p300. Kinetic characterization of its histone acetyltransferase activity. J. Biol. Chem. 2001, 276, 33721-33729.
66. Zheng, Y.; Thompson, P. R.; Cebrat, M.; Wang, L.; Devlin, M. K.; Alani, R. M.; Cole, P. A. Selective HAT inhibitors as mechanistic tools for protein acetylation. Methods Enzymol. 2004, 376, 188-199.
67. Cebrat, M.; Kim, C. M.; Thompson, P. R.; Daugherty, M.; Cole, P. A. Synthesis and analysis of potential prodrugs of coenzyme A analogues for the inhibition of the histone acetyltransferase p300. Bioorg. Med. Chem. 2003, 11, 3307-3313.
68. Poux, A. N.; Cebrat, M.; Kim, C. M.; Cole, P. A.; Marmorstein, R. Structure of the GCN5 histone acetyltransferase bound to a bisubstrate inhibitor. Proc. Natl. Acad. Sci. USA 2002, 99, 14065-14070.
69. Sagar, V.; Zheng, W.; Thompson, P. R.; Cole, P. A. Bisubstrate analogue structure-activity relationships for p300 histone acetyltransferase inhibitors. Bioorg. Med. Chem. 2004, 12, 3383-3390.
70. Zheng, Y.; Balasubramanyam, K.; Cebrat, M.; Buck, D.; Guidez, F.; Zelent, A.; Alani, R. M.; Cole, P. A. Synthesis and evaluation of a potent and selective cell-permeable p300 histone acetyltransferase inhibitor. J. Am. Chem. Soc. 2005, 127, 17182-17183.
71. Trehin, R.; Merkle, H. P. Chances and pitfalls of cell penetrating peptides for cellular drug delivery. Eur. J. Pharm. Biopharm. 2004, 58, 209-223.
72. Balasubramanyam, K.; Swaminathan, V.; Ranganathan, A.; Kundu, T. K. Small molecule modulators of histone acetyltransferase p300. J. Biol. Chem. 2003, 278, 19134-19140.
73. Balasubramanyam, K.; Varier, R. A.; Altaf, M.; Swaminathan, V.; Siddappa, N. B.; Ranga, U.; Kundu, T. K. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J. Biol. Chem. 2004, 279, 51163-51171.
74. Balasubramanyam, K.; Altaf, M.; Varier, R. A.; Swaminathan, V.; Ravindran, A.; Sadhale, P. P.; Kundu, T. K. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J. Biol. Chem. 2004, 279, 33716-33726.
75. Costi, R.; Di Santo, R.; Artico, M.; Miele, G.; Valentini, P.; Novellino, E.; Cereseto, A. Cinnamoyl compounds as simple molecules that inhibit p300 histone acetyltransferase. J. Med. Chem. 2007, 50, 1973-1977.